- Details
- Gianluca Giannarini joins Ashish Kamat to discuss a recent publication from European Urology Oncology, an editorial titled, "Urologists, You’ll Never Walk Alone! How Novel Immunotherapy and Modern Imaging May Change the Management of Non–muscle-invasive Bladder Cancer". Dr. Giannarini discusses the management of patients with high-risk non–muscle-invasive bladder cancer (NMIBC), especially those w...
|
- Details
- In this 2021 LUGPA MCE presentation, Noah Hahn presents Systemic Therapies in Advanced Bladder Cancer. He reviews the current data and experiences with immune checkpoint inhibitor therapies, (ICI) targeted therapies, and antibody-drug conjugate (ADC) therapies. Biographies: Noah M. Hahn, MD, Professor of Oncology and Urology, Department of Oncology and Urology, Johns Hopkins University School of M...
|
- Details
- Ashish Kamat is joined by Marek Babjuk, Morgan Roupret, and Wassim Kassouf for a rapid-fire debate on the management of small local recurrence low-grade bladder tumors with negative cytology. The patient in this debate is an 81-year-old male with multiple medical comorbidities. Dr. Morgan Roupret argues for formal TURBT with intravesical chemotherapy while Dr. Wassim Kassouf argues for active surv...
|
- Details
- In this discussion, Ashish Kamat speaks with Dan Theodorescu. Dr. Theodorescu presents his lab's novel findings on a unique epithelial cell subpopulation called "C3," identified using single-cell sequencing in muscle-invasive, non-metastatic tumors. This subpopulation predicts responses to chemotherapy and immune checkpoint inhibitors, offering new possibilities for targeted therapy. He also intro...
|
- Details
- Lydia Makaroff, Stephanie Chisolm, and Alex Filicevas join Ashish Kamat on UroToday's Bladder Cancer Center of Excellence for a round table discussion on the importance of bladder cancer from a patient perspective and recent efforts by The World Bladder Cancer Patient Coalition. Their recently launched evidence generation study, or bladder cancer patient survey, aims to capture bladder cancer pati...
|
- Details
- Ashish Kamat and Sumeet Bhanvadia, discuss the burden and impact of financial toxicity amongst a diverse population in bladder cancer patients. This conversation kicks off with a background on financial toxicity and how it may affect patient outcomes. Dr. Bhanvadia goes on to discuss the social and clinical determinants of financial toxicity among a diverse sample of bladder cancer patients. Dr. B...
|
- Details
- Richard Matulewicz joins Ashish Kamat presenting findings on the association of smoking status on recurrence of non-muscle invasive bladder cancer (NMIBC) in a contemporary cohort of patients with predominantly high-risk, recurrent NMIBC managed with photodynamic enhanced cystoscopy. A retrospective study was conducted in a multi-institutional registry. Smoking has a strong causal association with...
|
- Details
- Stephen Williams joins Ashish Kamat presenting findings on macro and microeconomics of blue light cystoscopy (BLC) with CYSVIEW® in the care of patients with non-muscle invasive bladder cancer, a Urologic Oncology Seminars and Original Investigations publication. The aim of the study was to determine the estimated budget impact to practices that incorporate blue light cystoscopy with hexaminolevul...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss a recently published paper, entitled, “ctDNA Guiding Adjuvant Immunotherapy in Urothelial Carcinoma.” They discuss the basics of circulating tumor DNA (ctDNA). He specifically discusses how we can use ctDNA to identify molecularly, or microscopic, residual disease. The study shows that ctDNA-positive patients with adjuvant atezolizumab, after surgery...
|
- Details
- Ashish Kamat, MD, MBBS, and Bishoy Faltas, MD, discuss immuno-oncology approaches across the spectrum of urothelial carcinoma. They discuss chemotherapy coupled with immune checkpoint inhibitors and how the combination may benefit patients with urothelial cancers. Further, they discuss the JAVELIN Bladder 100 trial, a randomized 700 patient trial that evaluated maintenance avelumab treatment. Biog...
|
